A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

Running, not enrolling

Conditions studied: Alzheimer's Disease

In brief

The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.

Key facts

Study ID

NCT06043700

Run by

Eisai Limited

People needed

2000

Starts

2023-09-12

Expected to finish

2028-03-31

Last updated by the study team

2026-03-05

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female, age 50 to 80 years inclusive, at the time of informed consent
• Those 50 to 64 years of age must have 1 of the following risk factors confirmed prior to blood sample collection:
• First degree relative with dementia onset before age 75,
• Known before screening to have at least 1 Apolipoprotein E4 (APOE4) allele, or
• Known before screening to have elevated brain amyloid according to previous positron emission tomography (PET), cerebrospinal fluid (CSF), or blood testing
• Provide written informed consent
• Willing and able to comply with all aspects of the protocol
• Willing to be referred to a clinical site if the assessment results meet the criteria

You may not qualify if…

• Known uncontrolled medical conditions (example, cardiac, respiratory, gastrointestinal, psychiatric, renal disease, malignant neoplasm)
• Participation in an interventional clinical trial study at the time of consent

Where it is running

• Eisai Site #3 — Clermont, Florida, United States
• Eisai Site #1 — Lady Lake, Florida, United States
• Eisai Site #2 — District Heights, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.